Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, today announces it has raised €3.5M (approx. $4M) from BNP Développement, Kreaxi and Bernard Chauvin, all historical investors. This Series A funding is composed of €1.75M ($2M) in capital and the remaining €1.75M in bank loans. Since its founding in 2017, Ciliatech has raised €6M ($6.5M).

Complete press release Ciliatech